Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
Phase 3
Active, not recruiting
- Conditions
- Hypertension
- Interventions
- Drug: LCZ/AML 200 mg/2.5 mgDrug: LCZ/AML 200 mg/5 mgDrug: LCZ/AML 200 mg/10 mgDrug: LCZ
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 718
- Registration Number
- NCT06236061
- Locations
- 🇯🇵
Novartis Investigative Site, Osaka, Japan
Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials
Completed
- Conditions
- Chronic Iron Overload
- Interventions
- Other: Physician survey
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 400
- Registration Number
- NCT06215287
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland
Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)
Completed
- Conditions
- Chronic Myeloid Leukemia With T315I Mutation
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT06211153
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
Completed
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration
- First Posted Date
- 2023-12-28
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2079
- Registration Number
- NCT06184360
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 414
- Registration Number
- NCT06178770
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Real-World Use of Novel Treatments in Patients With Spinal Muscular Atrophy (SMA): A Multi-Site Retrospective Chart Review of Pediatric SMA Patients Outside of the United States
Completed
- Conditions
- Spinal Muscular Atrophy
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT06178393
- Locations
- 🇺🇸
Novartis, Bannockburn, Illinois, United States
Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry
Completed
- Conditions
- PsoriasisPsoriatic Arthritis
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1171
- Registration Number
- NCT06172426
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States
Completed
- Conditions
- Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 287
- Registration Number
- NCT06161051
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Kesimpta Pregnancy and Infant Safety Study Using Real World Data
Recruiting
- Conditions
- Multiple Sclerosis
- Interventions
- Other: Multiple sclerosis disease modifying drug
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1500
- Registration Number
- NCT06156683
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
Recruiting
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- Other: ofatumumab
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 294
- Registration Number
- NCT06157086
- Locations
- 🇫🇷
Novartis Investigative Site, Villeurbanne, France
© Copyright 2025. All Rights Reserved by MedPath